KR101324340B1 - (3ｒ)-1-(2-메틸알라닐-ｄ-트립토필)-3-(페닐메틸)-3-피페리딘카르복실산 1,2,2-트리메틸하이드라지드의 결정 형태 - Google Patents

(3ｒ)-1-(2-메틸알라닐-ｄ-트립토필)-3-(페닐메틸)-3-피페리딘카르복실산 1,2,2-트리메틸하이드라지드의 결정 형태 Download PDF

Info

Publication number
KR101324340B1
KR101324340B1 KR1020067026722A KR20067026722A KR101324340B1 KR 101324340 B1 KR101324340 B1 KR 101324340B1 KR 1020067026722 A KR1020067026722 A KR 1020067026722A KR 20067026722 A KR20067026722 A KR 20067026722A KR 101324340 B1 KR101324340 B1 KR 101324340B1
Authority
KR
South Korea
Prior art keywords
delete delete
methylalanyl
phenylmethyl
trimethylhydrazide
piperidinecarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067026722A
Other languages
English (en)
Korean (ko)
Other versions
KR20070030222A (ko
Inventor
케이트 로리메르
시몬 에이치. 파인스
Original Assignee
헬신 세라퓨틱스 (유.에스.) 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헬신 세라퓨틱스 (유.에스.) 인크. filed Critical 헬신 세라퓨틱스 (유.에스.) 인크.
Publication of KR20070030222A publication Critical patent/KR20070030222A/ko
Application granted granted Critical
Publication of KR101324340B1 publication Critical patent/KR101324340B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
KR1020067026722A 2004-06-29 2005-06-22 (3ｒ)-1-(2-메틸알라닐-ｄ-트립토필)-3-(페닐메틸)-3-피페리딘카르복실산 1,2,2-트리메틸하이드라지드의 결정 형태 Expired - Lifetime KR101324340B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58375704P 2004-06-29 2004-06-29
US60/583,757 2004-06-29
PCT/US2005/022408 WO2006016995A1 (en) 2004-06-29 2005-06-22 Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide

Publications (2)

Publication Number Publication Date
KR20070030222A KR20070030222A (ko) 2007-03-15
KR101324340B1 true KR101324340B1 (ko) 2013-10-31

Family

ID=35064648

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067026722A Expired - Lifetime KR101324340B1 (ko) 2004-06-29 2005-06-22 (3ｒ)-1-(2-메틸알라닐-ｄ-트립토필)-3-(페닐메틸)-3-피페리딘카르복실산 1,2,2-트리메틸하이드라지드의 결정 형태

Country Status (9)

Country Link
US (2) US7825138B2 (enExample)
EP (2) EP1768976B1 (enExample)
JP (2) JP5122950B2 (enExample)
KR (1) KR101324340B1 (enExample)
CN (3) CN1976921B (enExample)
CA (1) CA2572325C (enExample)
IL (1) IL180336A0 (enExample)
MX (1) MXPA06015003A (enExample)
WO (1) WO2006016995A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281701A1 (en) 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
CN1976921B (zh) * 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CA2900322C (en) * 2013-02-21 2019-03-26 Pfizer Inc. Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
HUE046894T2 (hu) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Anamorelinen alapuló gyógyászati kezelések
CN107001323A (zh) * 2015-10-20 2017-08-01 江苏恒瑞医药股份有限公司 一种阿拉莫林的结晶形式及其制备方法
US9837965B1 (en) 2016-09-16 2017-12-05 Peregrine Semiconductor Corporation Standby voltage condition for fast RF amplifier bias recovery
US20220323430A1 (en) 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576648B2 (en) * 1999-11-10 2003-06-10 Novo Nordisk A/S Compound with growth hormone releasing properties

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960705808A (ko) * 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
JP4425992B2 (ja) * 1996-07-22 2010-03-03 サファイア セラピューティクス，インコーポレイティド 成長ホルモン放出特性を有する化合物
WO1999036431A1 (en) * 1998-01-16 1999-07-22 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2329881C (en) * 1998-05-11 2010-03-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
JP2007531769A (ja) * 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
CN1976921B (zh) 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576648B2 (en) * 1999-11-10 2003-06-10 Novo Nordisk A/S Compound with growth hormone releasing properties

Also Published As

Publication number Publication date
JP2008505078A (ja) 2008-02-21
CN102584937A (zh) 2012-07-18
US7825138B2 (en) 2010-11-02
CA2572325A1 (en) 2006-02-16
US20110003996A1 (en) 2011-01-06
CN103772483A (zh) 2014-05-07
EP1768976B1 (en) 2017-04-26
EP2298760B1 (en) 2015-08-05
JP5718286B2 (ja) 2015-05-13
US8466173B2 (en) 2013-06-18
IL180336A0 (en) 2007-07-04
EP2298760A1 (en) 2011-03-23
CN1976921B (zh) 2013-08-21
JP2012188452A (ja) 2012-10-04
EP1768976A1 (en) 2007-04-04
WO2006016995A1 (en) 2006-02-16
CA2572325C (en) 2013-08-27
CN102584937B (zh) 2017-03-01
JP5122950B2 (ja) 2013-01-16
CN1976921A (zh) 2007-06-06
HK1105000A1 (en) 2008-02-01
US20070004638A1 (en) 2007-01-04
KR20070030222A (ko) 2007-03-15
MXPA06015003A (es) 2007-08-07

Similar Documents

Publication Publication Date Title
JP5718286B2 (ja) （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形
ES2326654T3 (es) Metanosulfonato del ester etilico del acido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propionico de la formula a y su uso como medicamento.
JP7561240B2 (ja) ピリジノイルピペリジン５－ｈｔ１ｆアゴニストに関する組成物および方法
WO2010055082A2 (en) New crystal form of sunitinib malate
EP1060190A1 (en) New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide
JP2025510292A (ja) ５－ＭｅＯ－ＤＭＴの結晶性臭化水素酸塩
TW201829423A (zh) Ｊａｎｕｓ激酶抑制劑之結晶型
US8207217B2 (en) Crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan
US9975921B2 (en) Crystal forms of anamorelin
AU2005272074B2 (en) Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
HK1105000B (en) Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1, 2, 2-trimethylhydrazide
KR20080032144A (ko) 신규 염 ⅱ
HK1197827A (en) Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
US6281247B1 (en) Salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)amide
JP4707115B2 (ja) トリテルペン誘導体の新規結晶
CZ20003152A3 (cs) Soli N-methyi-N-((lR)-l-(N-methyl-N-((lR)-l- (methylkarbamoyl)-2-fenylethyl)karbamoyl)-2 (2-naftyl)ethyl)amidu (2E)-5-amino-5-methylhex- 2-enové kyseliny

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20061219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100617

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120327

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20121228

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120327

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20130125

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20121228

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20130730

Appeal identifier: 2013101000551

Request date: 20130125

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20130125

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20130125

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20120823

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20100617

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130316

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20130730

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20130226

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20131025

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20131025

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20181015

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20181015

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20191001

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20191001

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20210927

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20220922

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20230921

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20240925

Start annual number: 12

End annual number: 12